DENVER--(BUSINESS WIRE)--Sept. 7, 2006--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced the initiation of ARIES-3 (AMB-323), a Phase 3 long-term, open-label safety and efficacy study of ambrisentan in a broad population of patients with pulmonary hypertension (PH).
